The board of directors of GlaxoSmithKline Plc has issued a strong endorsement of the company’s chief executive Emma Walmsley a day after activist investor Elliott Advisors called on it to appoint new members and review the executive leadership at the company. Elliott reportedly started accumulating shares in GSK in April, just weeks before the UK company gave details about its plans to spin out its consumer healthcare division and consolidate its vaccine and pharma businesses in the company New GSK.
